FIMECS Presents at the 7th TPD & Induced Proximity Summit

Kanagawa, Japan, 25 October 2024 – FIMECS, Inc. ("FIMECS"), a private biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that the results of its research on targeted protein degraders based on its platform technology, RaPPIDS™, will be presented in a poster presentation at the 7th Targeted Protein Degradation & Induced Proximity Summit (28th-31st October 2024 in Boston, MA, USA).
For more information:
https://proteindegradation.com/

Title: RaPPIDS™ Platform to Accelerate TPD Drug Discovery with High-throughput Synthesis and Screening
Presenters: Shinya Yokosaka, Kazuteru Aoki, Shigeru Furukubo, Ryoma Hara, Michiko Watanabe, Tomoaki Hayashi, Rumiko Ono, Toshitake Kobayashi, Kanae Gamo, Yusuke Tominari
Time and date: 15:00-16:00 (local time), Tuesday, October 29, 2024

About FIMECS, Inc.

FIMECS, Inc. is developing a new class of drugs based on targeted protein degradation for the currently 'undruggable' targets in immuno-oncology and oncology areas. The company became able to discover drug candidates for inducing the degradation of disease-relevant targeted proteins by integrating proprietary E3 ligase binders and RaPPIDS™ platform. This drug discovery platform will help providing drugs to the patients all over the world through various internal and collaboration projects. https://www.fimecs.com/eng/

About RaPPIDS™

RaPPIDS™ (Rapid Protein Proteolysis Inducer Discovery System) is one of the proprietary drug discovery platforms of FIMECS, Inc. used to generate therapeutic candidates of the targeted protein degrader. The platform allows synthesizing and evaluating various degraders quickly based on the company's proprietary know-how and diversity-oriented synthesis, and delivery of the drug candidates with the best combination of target protein binders, linkers, and E3 ligase binders. Moreover, RaPPIDS™ platform enables the discovery of novel E3 ligase binders, which is expected to dramatically expand the range of target proteins that can be degraded.

# # #

FIMECS, Inc. Media and Investor Contact:
FIMECS, Inc.
26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan
Tel: +81-466-96-0261
Email: info@fimecs.com